Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX. Chau I, et al. Eur J Cancer. 2017 Aug;81:17-25. doi: 10.1016/j.ejca.2017.05.001. Epub 2017 Jun 4. Eur J Cancer. 2017. PMID: 28591675 Clinical Trial.
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.
Saini A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, Hickish T, Iveson T, Lofts F, Jodrell D, Ross PJ, Oates J. Saini A, et al. Among authors: chau i. Br J Cancer. 2003 Jun 16;88(12):1859-65. doi: 10.1038/sj.bjc.6600995. Br J Cancer. 2003. PMID: 12799627 Free PMC article. Clinical Trial.
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Chau I, Norman AR, Cunningham D, Waters JS, Topham C, Middleton G, Hill M, Ross PJ, Katopodis R, Stewart G, Oates JR. Chau I, et al. Br J Cancer. 2004 Oct 18;91(8):1453-8. doi: 10.1038/sj.bjc.6602169. Br J Cancer. 2004. PMID: 15365570 Free PMC article. Clinical Trial.
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer.
Chau I, Norman AR, Cunningham D, Iveson T, Hill M, Hickish T, Lofts F, Jodrell D, Webb A, Tait D, Ross PJ, Shellito P, Oates JR. Chau I, et al. Eur J Cancer. 2005 Jul;41(11):1551-9. doi: 10.1016/j.ejca.2005.01.027. Eur J Cancer. 2005. PMID: 16026692 Clinical Trial.
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
Chau I, Norman AR, Cunningham D, Oates J, Hawkins R, Iveson T, Nicolson M, Harper P, Seymour M, Hickish T. Chau I, et al. Ann Oncol. 2009 May;20(5):885-91. doi: 10.1093/annonc/mdn716. Epub 2009 Jan 22. Ann Oncol. 2009. PMID: 19164454 Free article.
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
Starling N, Okines A, Cunningham D, Allum W, Wotherspoon A, Benson M, Thompson J, Thomas J, Brown G, Riddell A, Stavridi F, Ashley S, Oates J, Chau I. Starling N, et al. Among authors: chau i. Br J Cancer. 2009 Jun 2;100(11):1725-30. doi: 10.1038/sj.bjc.6605070. Epub 2009 May 12. Br J Cancer. 2009. PMID: 19436301 Free PMC article. Clinical Trial.
426 results